C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 5, 2007, Pages 1047-1054

  Pannell, R ^a   Kung, W ^a   Gurewich, Victor ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

C1 inhibitor; Fibrin specificity; Fibrinolysis; Mutant prourokinase

Indexed keywords

COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRIN; MUTANT PROTEIN; PLASMIN; PLASMINOGEN; PROUROKINASE; UROKINASE;

ARTICLE; BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; FIBRINOGENOLYSIS; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; PLASMA; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SAFETY; ZYMOGRAPHY;

COMPLEMENT C1 INACTIVATOR PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRIN; FIBRINOLYSIS; HUMANS; PLASMINOGEN; SERPINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 34247871522     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02453.x     Document Type: Article

References (23)

1. Rao AK, Pratt C, Berke A, Jaffe A, Ockene LI, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in myocardial infarction (TIMI) trial-phase 1: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Amer Coll Cardiol USA 1988; 11: 1-11.
2. Fennerty AG, Levine MN, Hirsh J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1989; 95: 88S-97S.
3. Braunwald E, Knatterud GL, Passamani ER, Robertson TL. Announcement of protocol change in thrombolysis in myocardial infarction trial (abstr.). J Amer Coll Cardiol 1987; 9: 467.
4. Grossbard EB. Genetech experience with rt-PA (activase) (abstr.). J Amer Coll Cardiol 1987; 9: 467.
5. Meyer J, Bar F, Barth H. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction: PRIMI Trial Study Group. Lancet 1989; 1: 863-8.
6. Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry 1996; 35: 14070-6.
7. Sun Z, Jiang Y, Ma Z, Wu H, Liu BF, Xu Y, Tang W, Chen Y, Li C, Zhu D, Gurewich V, Liu JN. Identification of a flexible loop (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity. J Biol Chem 1997; 272: 23818-23.
8. Liu JN, Liu JX, Liu BF, Sun Z, Zuo JL, Zhang PX, Zhang J, Chen YH, Gurewich V. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis. Circ Res 2002; 90: 757-63.
9. Gurewich V, Pannell R, Simmons-Byrd A, Sarmientos P, Liu JN, Badylak SF. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator. J Thromb Haemost 2006; 4: 1559-65.
10. Liu JN, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991; 88: 2012-7.
11. Granelli-Pipero A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-34.
12. Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator specific inhibitor by cultured human monocytes macrophages. J Exp Med 1984; 159: 1653-8.
13. Pannell R, Gurewich V. The activation of plasminogen by single-chain urokinase or by two-chain urokinase -a demonstration that single chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22-6.
14. Harpel PC. C1 inactivator inhibition by plasmin. J Clin Invest 1970; 49: 568-75.
15. Murano G, Arnoson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma. Blood 1980; 55: 430-6.
16. Huisman LG, van Griensven JM, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73: 466-71.
17. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52: 91-112.
18. Bennett WR, Yawn DH, Migliore PJ, Young JB, Pratt CM, Raizner AE, Roberts R, Bolli R. Activation of the complement system by recombinant tissue plasminogen activator. J Amer Coll Cardiol 1987; 10: 627-32.
19. Juhan-Vague I, Moerman B, deCock F, Aillaud MR, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-30.
20. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
21. Liu JN, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK). Biochemistry 1992; 31: 6311-7.
22. Hoffmeister HM, Szabo S, Helber U, Seipel L. The thrombolytic paradox. Thromb Res 2001; 103: S51-5.
23. Torr SR, Nachowiak DA, Fujii S, Sobel BE. "Plasminogen steal"and clot lysis. J Amer Coll Cardiol 1992; 19: 1085-90.